Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in health...
Main Authors: | Sudhir Mehta, Sudhir Bhandari, Shaurya Mehta |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Journal of Global Antimicrobial Resistance |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716520301946 |
Similar Items
-
Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen
by: Anil Pareek, et al.
Published: (2020-01-01) -
Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers
by: Habib M R. Karim, et al.
Published: (2020-01-01) -
Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models
by: Kyle Rosenke, et al.
Published: (2020-12-01) -
SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis
by: Khalid M. Dousa, et al.
Published: (2020-01-01) -
Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection
by: Reetika Malik Yadav, et al.
Published: (2021-05-01)